Braveheart Bio, Inc. (BRVE)

29.20 +1.49 (+5.38%) USD  |  NASDAQ  |  Sep 18, 16:00
28.95 -0.25 (-0.86%) After-Hours: 20:00
More

Braveheart Bio Shareholders Equity (Quarterly) : 117.61M for June 30, 2026

Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for BRVE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2026. Start Trial.
Date Value
June 30, 2026 117.61M
Date Value
March 31, 2026 71.49M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Bristol Myers Squibb Co. 22.32B
ANI Pharmaceuticals, Inc. 597.21M
Corcept Therapeutics, Inc. 705.78M
Veru, Inc. 28.38M
IGC Pharma, Inc. 6.132M

Shareholders Equity (Quarterly) Related Metrics

Total Assets (Quarterly) 126.96M
Total Liabilities (Quarterly) 9.342M
Debt to Equity Ratio 0.0049
Current Ratio 13.63